- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Amy P. Abernethy, MD, PhD | Authors
It's Time to Have ‘The Talk’: Cost Communication and Patient-Centered Care
June 15, 2014
Barriers to cost discussions fall into three categories: inaccessible cost data, ethical concerns, and insufficient training.
A Comparison of FDA and EMA Drug Approval: Implications for Drug Development and Cost of Care
December 15, 2013
The development and approval of oncology therapeutics has been facilitated by the cooperation and coordination of regulatory practices between the EMA and the FDA. However, there continue to be important differences between the decisions of the two agencies.
Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
April 15, 2013
Just as high-quality research has focused on limiting the physical toxicity resulting from successful treatment, future research should focus on mitigating the negative effects of financial toxicity without affecting disease-related outcomes.
Financial Toxicity, Part I: A New Name for a Growing Problem
February 15, 2013
Costs of care continue to rise; new cancer drugs are more expensive than ever before, and more patients are being treated with these drugs. While patients and claims datasets consistently report an association between financial burden and quality of care, the impact on traditional disease-related outcomes-survival, for example-have not been assessed.
The Need for Community-Based Palliative Care for Patients Living With Cancer
November 30, 2011
As Dennis et al demonstrate, palliative care (PC) is a unique and multifaceted philosophy of care geared towards patients living with serious illness, not only those dying from it.